Crelosidenib
Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes[1].
Product Specifications
CAS Number
2230263-60-0
Product Name Alternative
LY3410738; Mutant IDH1-IN-6
UNSPSC
12352005
Target
Isocitrate Dehydrogenase (IDH)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mutant-idh1-in-6.html
Solubility
10 mM in DMSO
Smiles
O=C1OCC2=CN=C(N[C@H](C3=CC=C([C@@H](N4CCN(C(C=C)=O)CC4)CC5CC5)C=C3)C)N=C2N1CC
Molecular Formula
C28H36N6O3
Molecular Weight
504.62
References & Citations
[1]Renato Alejandro BAUER, et al. 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors. WO2018111707A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
IDH1; IDH2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD40 / TNFRSF5 / CD40L-Receptor (C40/2383), CF640R conjugate, 0.1mg/mL
